Evaluating Equipment Utility and Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Equipment Utility and Innovation
A survey shows satisfaction with utility and innovation in most solid dosage and parenteral drug-manufacturing equipment.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 110-113

QbD


Figure 3: Application of quality-by-design (QbD) principles to manufacturing processes (% of respondents).
Almost half of respondents indicated that their company applies QbD principles for both new and legacy products, and another 32% apply QbD to all or select new products (see Figure 3). Only 22% of respondents do not apply QbD at all. Approximately 72% identified better process understanding as a benefit of QbD. Participants were invited to choose all answers that applied, and they indicated other benefits of QbD as increased efficiency/reduced waste (48%), reduced costs (44%), shorter process times (35%), streamlining regulatory review (32%), and improved ease of making changes (29%). Only 6% of respondents felt that there are no challenges or barriers to implementing QbD. More than half noted lack of knowledge and training as a problem. Approximately 42% indicated clarity of regulatory guidance as a barrier. Only about one-third of repondents chose, respectively, lack of management buy in, availability of software, or availability of equipment as barriers to QbD implementation.

PAT


Figure 4: Current and future use of process analytical technology (PAT) (% of respondents).
Over half of respondents indicate that they use PAT, which is an increase from last year’s survey that found only 40% of respondents incorporating PAT (1). When asked to indicate the primary drivers for using PAT (multiple answers permitted), nearly half of respondents chose increased efficiency/reduced waste; others chose better process understanding (44%), reduced costs (33%), and shorter process times (31%). Almost 10% indicated that their company mandates use of PAT, and nearly 6% said their customers request it. Sterile manufacturing/aseptic processing and lyophilization are areas of potentially strong growth for the use of PAT. As shown in Figure 4, 14% of respondents in these areas use PAT now, but an additional 50% plan to implement PAT in the coming year. Compared to the other categories, a higher percentage in solid-dosage manufacturing (22–26%) already use PAT, but a lower percentage (24–25%) plan to add PAT in the coming year.

Continuous manufacturing

Continuous manufacturing is still a new technology, but is being considered as an alternative to traditional batch processes for solid-dosage manufacturing. Respondents indicated (multiple answers permitted) multiple barriers to implementing continuous processes, including:

  • lack of equipment (46%)
  • insufficient expertise (42%)
  • cost (36%)
  • concern over regulatory acceptance (29%)
  • insufficient PAT (23%)
  • lack of appropriate documentation systems (15%).

Nearly all agreed, however, that technology will continue to evolve and use of continuous processing will increase.

Respondents’ profiles

Pharmaceutical Technology’s Equipment and Manufacturing Survey targeted individuals in production and engineering. The survey was conducted by email in February 2013 and had 193 respondents. Nearly 30% were from innovator pharmaceutical companies, 28% from generic-drug companies, 20% from contract manufacturers, and 10% from consumer healthcare companies making over-the-counter products. The remaining respondents included excipient and raw material suppliers (7%) and equipment or machinery vendors (5%). About half of the respondents were involved with solid-dosage manufacturing and the other half in parenteral drug manufacturing. The majority of respondents (79%) were from companies with under $1 billion in revenue. Nearly 7% were from companies with between $1 to $10 billion in revenue, almost 7% were from companies with $10 to $50 billion in revenue, and the remainder (8%) were from companies with over $50 billion in revenue.

Reference

1. P. Van Arnum, Pharm. Techol. 36 (4) 50-60 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here